IL232173A0 - Cancer antigen presenting vaccine with gamma interferon - Google Patents

Cancer antigen presenting vaccine with gamma interferon

Info

Publication number
IL232173A0
IL232173A0 IL232173A IL23217314A IL232173A0 IL 232173 A0 IL232173 A0 IL 232173A0 IL 232173 A IL232173 A IL 232173A IL 23217314 A IL23217314 A IL 23217314A IL 232173 A0 IL232173 A0 IL 232173A0
Authority
IL
Israel
Prior art keywords
antigen presenting
cancer vaccine
gamma interferon
presenting cancer
interferon
Prior art date
Application number
IL232173A
Other languages
English (en)
Hebrew (he)
Original Assignee
California Stem Cell Inc
Andrew Cornforth
Robert Dillman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Stem Cell Inc, Andrew Cornforth, Robert Dillman filed Critical California Stem Cell Inc
Publication of IL232173A0 publication Critical patent/IL232173A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL232173A 2011-10-20 2014-04-22 Cancer antigen presenting vaccine with gamma interferon IL232173A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549681P 2011-10-20 2011-10-20
US201261594304P 2012-02-02 2012-02-02
PCT/US2012/061294 WO2013059778A2 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine with gamma interferon

Publications (1)

Publication Number Publication Date
IL232173A0 true IL232173A0 (en) 2014-06-30

Family

ID=48141460

Family Applications (2)

Application Number Title Priority Date Filing Date
IL232173A IL232173A0 (en) 2011-10-20 2014-04-22 Cancer antigen presenting vaccine with gamma interferon
IL232172A IL232172A0 (en) 2011-10-20 2014-04-22 Antigen presenting cancer vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL232172A IL232172A0 (en) 2011-10-20 2014-04-22 Antigen presenting cancer vaccine

Country Status (11)

Country Link
US (2) US9555058B2 (OSRAM)
EP (2) EP2768519A4 (OSRAM)
JP (2) JP2014530627A (OSRAM)
KR (2) KR20150016200A (OSRAM)
CN (5) CN105288602A (OSRAM)
AU (2) AU2012325764A1 (OSRAM)
CA (2) CA2852960A1 (OSRAM)
HK (2) HK1201176A1 (OSRAM)
IL (2) IL232173A0 (OSRAM)
SG (4) SG11201401631VA (OSRAM)
WO (2) WO2013059784A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865830B1 (fr) 2004-01-30 2006-05-19 Neopost Ind Systeme d'affranchissement de courrier a mode d'impression externe securise
CN105288602A (zh) 2011-10-20 2016-02-03 新干细胞肿瘤学有限责任公司 具有γ干扰素的抗原呈递癌症疫苗
CN103599528B (zh) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 人树突状细胞疫苗的制备方法
JP6967963B2 (ja) * 2014-07-17 2021-11-17 ブライアン ジェイ ツェルニキCZERNIECKI, Brian, J. 複数用量注射準備済樹状細胞ワクチンの製造ならびにｈｅｒ２およびｈｅｒ３を遮断するための併用療法
KR20180126085A (ko) * 2016-05-05 2018-11-26 난토믹스, 엘엘씨 체크포인트 부전 및 그 방법(checkpoint failure and methods therefor)
CA3053939A1 (en) * 2017-02-17 2018-08-23 Aivita Biomedical, Inc. Methods to enhance tumor immunogenicity and compositions for autologous cancer immunotherapeutic products using modified tumor cells and modified dendritic cells
WO2024107624A1 (en) * 2022-11-14 2024-05-23 Shattuck Labs, Inc. Methods of overcoming resistance to checkpoint inhibitor therapies
CN118441033B (zh) * 2024-04-24 2025-06-20 广西医科大学 HLA-DPB1*05:01在抗γ干扰素自身抗体所致获得性免疫缺陷筛查中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598998B1 (en) * 1992-09-07 2004-05-19 Kyowa Hakko Kogyo Co., Ltd Humanized antibodies reacting with the ganglioside GM2
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
CA2321093A1 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
AU8026800A (en) 1999-10-15 2001-04-30 Baylor Research Institute Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
DK1448229T3 (da) * 2001-11-29 2010-03-08 Dandrit Biotech As Farmaceutisk sammensætning til at inducere et immunrespons hos et menneske eller et dyr
GB0130720D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Proteins
CN1443778A (zh) * 2002-03-13 2003-09-24 上海中信国健药业有限公司 一种黑色素瘤相关抗原的单克隆抗体及其用途和药物组合物
US20060140983A1 (en) * 2004-10-25 2006-06-29 Baylor Research Institute Dendritic cells loaded with heat shocked melanoma cell bodies
WO2007016340A2 (en) * 2005-07-29 2007-02-08 Providence Health System Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response
EP1951318B1 (en) * 2005-11-07 2012-10-17 British Columbia Cancer Agency Inhibition of autophagy genes in cancer chemotherapy
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
EP2630968A1 (en) * 2006-06-30 2013-08-28 Baylor Research Institute Dendritic cells generated using GM-CSF and interferon alpha and loaded with heat-treated and killed cancer cells
AR060424A1 (es) 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same
CN105288602A (zh) 2011-10-20 2016-02-03 新干细胞肿瘤学有限责任公司 具有γ干扰素的抗原呈递癌症疫苗

Also Published As

Publication number Publication date
NZ623917A (en) 2016-09-30
SG11201401631VA (en) 2014-05-29
WO2013059778A3 (en) 2013-07-04
EP2768534A4 (en) 2015-04-01
KR20150004791A (ko) 2015-01-13
EP2768534A1 (en) 2014-08-27
JP2014530627A (ja) 2014-11-20
JP2014533938A (ja) 2014-12-18
HK1201175A1 (en) 2015-08-28
NZ623915A (en) 2016-02-26
SG10201602424RA (en) 2016-05-30
EP2768519A2 (en) 2014-08-27
WO2013059784A1 (en) 2013-04-25
SG10201508535RA (en) 2015-11-27
US9555058B2 (en) 2017-01-31
SG11201401632WA (en) 2014-05-29
CA2852960A1 (en) 2013-04-25
CN105288602A (zh) 2016-02-03
CN103917246A (zh) 2014-07-09
US20140308316A1 (en) 2014-10-16
CN103957925A (zh) 2014-07-30
CN105861437A (zh) 2016-08-17
CA2852967A1 (en) 2013-04-25
EP2768519A4 (en) 2015-07-01
WO2013059778A2 (en) 2013-04-25
CN105999249A (zh) 2016-10-12
HK1201176A1 (en) 2015-08-28
IL232172A0 (en) 2014-06-30
AU2012325758A1 (en) 2014-04-24
KR20150016200A (ko) 2015-02-11
US20140314814A1 (en) 2014-10-23
AU2012325764A1 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
ZA201500784B (en) Mycobacterial antigen vaccine
SG10201911616QA (en) Individualized vaccines for cancer
PL2804878T3 (pl) Przeciwciała anty-CXCR3
SG11201401631VA (en) Antigen presenting cancer vaccine with gamma interferon
IL231043A (en) vaccine
GB201120860D0 (en) Cancer immunotherapy
GB201003293D0 (en) Cancer vaccine
GB201119999D0 (en) Vaccine
ZA201402071B (en) Vaccine therapy
PL2591798T3 (pl) Szczepionka do zastosowania w immunoterapii nowotworów
SI2714071T1 (sl) Individualizirana cepiva proti raku
IL233928A0 (en) A pluripotent germ layer-derived antigen with anti-cancer properties
GB201120000D0 (en) Vaccine
GB201107549D0 (en) Cancer vaccine
GB201121647D0 (en) Vaccine
GB201108256D0 (en) Vaccine
GB201108986D0 (en) Vaccines
GB201108984D0 (en) Vaccines
GB201108982D0 (en) Vaccines